Epidemiological Study of Hepatitis B and Hepatitis C Infections in Northeastern China and the Beneficial Effect of the Vaccination Strategy for Hepatitis B: a Cross-sectional Study
Overview
Authors
Affiliations
Background: Viral hepatitis, mainly hepatitis B and C, is a serious public health problem worldwide. In China, the prevalence of hepatitis B virus (HBV) infection remains high, while that of hepatitis C virus (HCV) infection is controversial. This study investigated the epidemiology of HBV and HCV infections and assessed the beneficial effect of the vaccination strategy for hepatitis B in Northeastern China.
Methods: From June 2016 to August 2016, 6541 residents of Changchun in Northeastern China were recruited for this cross-sectional study. Demographic characteristics as well as HBV and HCV serological test results were reviewed and analyzed.
Results: Among all study participants, 3.8% and 0.36% tested positive for hepatitis B surface antigen (HBsAg) and anti-HCV, respectively. The HBsAg- and anti-HCV-positive rates were significantly higher in male participants (4.58% and 0.43%) than in female individuals (3.0% and 0.33%). Notably, among all age groups, the lowest rate of HBsAg positivity (0.2%) was found in children born after the implementation of the vaccination strategy for hepatitis B. Conversely, participants aged 40-49 years had significantly greater positive rates of HBsAg (5.9%) compared with those of other age groups. Furthermore, the highest rates of anti-HCV positivity (1.1%) were observed in participants aged 50-59 years.
Conclusions: The rate of HBsAg-positivity declined significantly following successful implementation of the policy on hepatitis B vaccination, indicating a beneficial impact on the control of HBV infection. However, only a slight decrease was observed in the anti-HCV-positivity rate, identifying an area in need of improvement within viral hepatitis prevention and control programs in China.
Meng X, Gillespie I, Dong J, Ning Y, Kendrick S Medicine (Baltimore). 2024; 103(7):e36645.
PMID: 38363906 PMC: 10869091. DOI: 10.1097/MD.0000000000036645.
Ejaz S, Abdullah I, Malik W, Anjum S, Ashraf M, Akhtar N Front Public Health. 2023; 11:1269209.
PMID: 38106902 PMC: 10721974. DOI: 10.3389/fpubh.2023.1269209.
Huang Y, Yang Y, Wu T, Li Z, Xu H, Huang A J Clin Transl Hepatol. 2022; 10(4):660-668.
PMID: 36062290 PMC: 9396322. DOI: 10.14218/JCTH.2021.00272.
Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region.
Iversen J, Wand H, Chan P, Le L, Maher L Viruses. 2022; 14(7).
PMID: 35891529 PMC: 9320901. DOI: 10.3390/v14071548.
Ren W, Wu Z, Liu Y, Qiu Y, Yao J, Ren J Hum Vaccin Immunother. 2022; 18(6):2096972.
PMID: 35878394 PMC: 9746406. DOI: 10.1080/21645515.2022.2096972.